Side-by-side comparison
Amgen vs Merck & Co.
As of Sep 25, 2026, P/E is 25.8x for Amgen vs 119.0x for Merck & Co.; P/S is 5.9x for Amgen vs 5.5x for Merck & Co.; revenue growth is 9.1% for Amgen vs 4.6% for Merck & Co.; net margin is 23.0% for Amgen vs 4.8% for Merck & Co..
Key metrics
| Metric | AMGN | MRK |
|---|---|---|
| Price | $414.61 | $148.78 |
| Market cap | $224.15B | $367.07B |
| P/E | 25.8x (#1) | 119.0x (#2) |
| P/S | 5.9x (#2) | 5.5x (#1) |
| Revenue growth | 9.1% (#1) | 4.6% (#2) |
| Operating margin | 30.0% (#1) | — |
| Net margin | 23.0% (#1) | 4.8% (#2) |
| Debt / equity | 4.44 (#2) | 1.22 (#1) |
| 1-year return | +51.9% (#2) | +89.4% (#1) |
| Research score | 67/100 (#1) | 51/100 (#2) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Amgen Inc. (AMGN) — Drug Manufacturers—General
- Merck & Co., Inc. (MRK) — Drug Manufacturers—General